Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: Results of a multicenter phase II international thyroid oncology group trial
Maria E. Cabanillas, Jonas A. De Souza, Susan Geyer, Lori J. Wirth, Michael E. Menefee, Stephen V. Liu, Komal Shah, John Wright, Manisha H. Shah
Dive into the research topics of 'Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: Results of a multicenter phase II international thyroid oncology group trial'. Together they form a unique fingerprint.